Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 4:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 134 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Selective serotonin re-uptake inhibitor Clear all
Completed Phase 1Phase 2 Interventional Results available

An Adaptive Treatment Strategy for Adolescent Depression-Continuation

NCT02017535
View directory record Official record
Conditions
Adolescent Depression
Interventions
Fluoxetine, Interpersonal Psychotherapy
Drug · Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 18 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Oct 10, 2026, 4:28 PM EDT
Completed Phase 4 Interventional Results available

Study of 6(S)-5-MTHF Among Selective Serotonin Reuptake Inhibitor-Resistant Outpatients With Major Depressive Disorder

NCT00955955
View directory record Official record
Conditions
Depression
Interventions
6(S)-5-MTHF(Deplin), Placebo
Other
Lead sponsor
George I. Papakostas
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
6
States / cities
San Diego, California • Chicago, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 10, 2026, 4:28 PM EDT
Completed Phase 1 Interventional Results available

A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive Medication

NCT04937829
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
5 mg BI 1569912, 20 mg BI 1569912, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
10
States / cities
Garden Grove, California • Torrance, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 10, 2026, 4:28 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Study to Evaluate the Effectiveness of Certain Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants During Pregnancy and Evaluate Newborn Outcomes

NCT00553917
View directory record Official record
Conditions
Depression
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 10, 2026, 4:28 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Allopregnanolone and Dynamic GABA-A Receptor Plasticity in Selective Serotonin Reuptake Inhibitor Responsive Premenstrual Dysphoric Disorder

NCT06704594
View directory record Official record
Conditions
Premenstrual Dysphoric Disorder (PMDD)
Interventions
sertraline 50 mg daily, Placebo Oral Tablet
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
288 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
2
States / cities
Baltimore, Maryland • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 10, 2026, 4:28 PM EDT
Completed Phase 4 Interventional Results available

The ISLAND Study: InSuLa Assessed Needs for Depression

NCT02137369
View directory record Official record
Conditions
Depression
Interventions
Selective serotonin re-uptake inhibitor, Cognitive Behavioral Therapy, Combination treatment (SSRI + CBT)
Drug · Behavioral · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 60 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Oct 10, 2026, 4:28 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Intranasal Esketamine to Maintain the Antidepressant Response to IV Racemic Ketamine

NCT04856124
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Intranasal esketamine
Drug
Lead sponsor
Psych Atlanta
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Marietta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2021 · Synced Oct 10, 2026, 4:28 PM EDT
Completed No phase listed Observational Results available

Combination Deplin® and Antidepressant Therapy for a Major Depressive Episode (MDE)- a Retrospective Analysis

NCT01001559
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
L-methylfolate, Selective serotonin reuptake inhibitor (SSRI), Serotonin and norepinephrine reuptake inhibitor (SNRI)
Drug
Lead sponsor
Pamlab, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Oct 10, 2026, 4:28 PM EDT
Terminated Phase 4 Interventional Results available

Seroquel Alone Versus Seroquel With an SSRI for Depression With Psychotic Symptoms

NCT00955474
View directory record Official record
Conditions
Major Depressive Disorder With Psychotic Features
Interventions
Quetiapine, escitalopram, Sertraline, Citalopram
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Oct 10, 2026, 4:28 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

SSRI Effects on Semen Parameters in Men

NCT00385762
View directory record Official record
Conditions
Healthy
Interventions
paroxetine
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 2, 2017 · Synced Oct 10, 2026, 4:28 PM EDT
Completed Phase 2 Interventional Results available

Optimizing the Effectiveness of Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment-Resistant Depression

NCT00093847
View directory record Official record
Conditions
Depression
Interventions
S-adenosyl methione (SAMe), Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 13, 2014 · Synced Oct 10, 2026, 4:28 PM EDT
Recruiting Phase 3 Interventional

Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

NCT06559306
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Seltorexant, Placebo, Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
84
States / cities
Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 10, 2026, 4:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Selective Serotonin Reuptake Inhibitors (SSRIs) and an Opioid on Ventilation

NCT05470465
View directory record Official record
Conditions
Hypercapnia, Ventilatory Depression
Interventions
Placebo and Oxycodone, Paroxetine and Oxycodone, Escitalopram and Oxycodone
Drug
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
18 Years to 50 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Oct 10, 2026, 4:28 PM EDT
Recruiting Phase 4 Interventional

Identifying and Treating Depression in the Orthopaedic Trauma Population

NCT05976347
View directory record Official record
Conditions
Depression
Interventions
Fluoxetine 20 MG, Duloxetine 30 MG, Observation
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 10, 2026, 4:28 PM EDT
Withdrawn Phase 1Phase 2 Interventional Accepts healthy volunteers

Dose-finding Study of Selective Serotonin Reuptake Inhibitors to Enhance Neuroplasticity

NCT04221256
View directory record Official record
Conditions
Stroke, Ischemic
Interventions
Administration of SSRI escitalopram, Paired Associative stimulation, Administration of Placebo
Drug · Behavioral
Lead sponsor
Burke Medical Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
White Plains, New York
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 10, 2026, 4:28 PM EDT
Completed Phase 4 Interventional Results available

Primary Care Intervention Strategy for Anxiety Disorders

NCT00347269
View directory record Official record
Conditions
Post-traumatic Stress Disorder, Generalized Anxiety Disorder, Panic Disorder, Social Anxiety Disorder
Interventions
Cognitive-behavioral therapy, Psychotropic medication optimization, Treatment as Usual
Behavioral · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 75 Years
Enrollment
1,004 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 1 more
Source: ClinicalTrials.gov public record
Updated May 19, 2017 · Synced Oct 10, 2026, 4:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Preventing Chronic Depression and PTSD in Stroke Patients Admitted to the Neuroscience Intensive Care Unit (NICU) and Their Family Caregivers

NCT02797509
View directory record Official record
Conditions
Neurological Disorder
Interventions
Psychosocial Skills-Based Intervention
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 17, 2018 · Synced Oct 10, 2026, 4:28 PM EDT
Completed Phase 4 Interventional Results available

Drug Therapy for Generalized Anxiety Disorder Among the Elderly

NCT00105586
View directory record Official record
Conditions
Anxiety Disorders, Generalized Anxiety Disorder
Interventions
Escitalopram
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
60 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Oct 10, 2026, 4:28 PM EDT
Terminated Phase 1 Interventional

A Proof of Concept Study of the Prevention of Mild Cognitive Impairment and Eventual Alzheimer's Disease Using F18 Flutemetamol

NCT03274817
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Escitalopram Pill, Venlafaxine Pill, Placebo Oral Tablet
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
60 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2020 · Synced Oct 10, 2026, 4:28 PM EDT
Terminated No phase listed Observational

Functional and Neurochemical Correlates of Treatment Response in Major Depressive Disorder

NCT01598324
View directory record Official record
Conditions
Treatment-Resistant Depression
Interventions
Not listed
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2013 · Synced Oct 10, 2026, 4:28 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)

NCT03018340
View directory record Official record
Conditions
Adjunctive Treatment of Major Depressive Disorder
Interventions
Pimavanserin, Placebo
Drug · Other
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
36
States / cities
Birmingham, Alabama • Rogers, Arkansas • Garden Grove, California + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Oct 10, 2026, 4:28 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Differentiating Unipolar and Bipolar Depression in Young Adults Using fMRI

NCT01811147
View directory record Official record
Conditions
Bipolar Disorder, Major Depression
Interventions
Selective Serotonin Reuptake Inhibitor (SSRI)
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
15 Years to 30 Years
Enrollment
192 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Oct 10, 2026, 4:28 PM EDT
Suspended Phase 3 Interventional

Feasibility Trial of Tele-IPT and Tele-Pharmacotherapy for Patients With Depression and Non-Metastatic Breast Cancer

NCT04973930
View directory record Official record
Conditions
Major Depressive Disorder, Breast Cancer, Venlafaxine
Interventions
Interpersonal Psychotherapy, Venlafaxine HCl ER
Behavioral · Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 10, 2026, 4:28 PM EDT
Completed Phase 4 Interventional

Predicting Treatment Response in Patients With OCD

NCT03993535
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
selective serotonin reuptake inhibitor
Drug
Lead sponsor
University of Sao Paulo
Other
Eligibility
18 Years to 50 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 10, 2026, 4:28 PM EDT